Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 21Neoplasm Metastasis 3Sleep Initiation and Maintenance Disorders 1Prostatic Diseases 1Prostate Cancer Metastatic Disease 1Neoadjuvant Therapy 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Neoplasms 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1High Risk Prostate Cancer 1Hematologic Neoplasms 1Genital Diseases, Male 1Fatigue 1Depression 1Adenocarcinoma 1

Interventions

darolutamide 2gedatolisib 1enzalutamide 1apalutamide 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Genital Diseases, Male × apalutamide × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡